Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.
Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).
Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.
Disclosures: The study received no funding. The authors declared no conflict of interests.
Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008 .